POL humane challenge
K |
|||
Zeile 28: | Zeile 28: | ||
{{tp|p=33137284|t=2020. COVID-19 human challenge studies in the UK.|pdf=|usr=020}} | {{tp|p=33137284|t=2020. COVID-19 human challenge studies in the UK.|pdf=|usr=020}} | ||
{{tp|p=33154089|t=2020. Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?|pdf=|usr=023}} | {{tp|p=33154089|t=2020. Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?|pdf=|usr=023}} | ||
+ | {{tp|p=33235368|t=2020. The COVID vaccine challenges that lie ahead.|pdf=|usr=021}} | ||
+ | {{tp|p=33236048|t=2020. Challenge Trials: What Are the Ethical Problems?|pdf=|usr=021}} | ||
+ | {{tp|p=33249450|t=2020. Assessment of risks associated with SARS-CoV-2 experimental human infection studies.|pdf=|usr=021}} |
Version vom 30. Dezember 2020, 22:24 Uhr
Politics main page |
POL research ethics |
Nuremberg was for nazis only and UK is not Europe
32218549 2020. Should scientists infect healthy people with the coronavirus to test vaccines?
32241929 2020. Infect volunteers to speed a coronavirus vaccine?
32322034 2020. Hundreds of people volunteer to be infected with coronavirus.
32461245 2020. Ethical guidelines for deliberately infecting volunteers with COVID-19.
32469074 2020. Paying Participants in COVID-19 Trials.
32414757 2020. Ethical considerations for epidemic vaccine trials.
32479747 2020. COVID-19 human challenge studies: ethical issues.
32496536 2020. SARS-CoV-2 Human Challenge Trials: Too Risky, Too Soon.
32635912 2020. Exploring the acceptability of controlled human infection with SARSCoV2-a public consultation.
32669462 2020. Human Infection Challenge Studies: a Test for the Social Value Criterion of Research Ethics.
32616623 2020. Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia.
32795408 2020. Evolving ethics of COVID-19 challenge trials.
32851596 2020. COVID-19 vaccines: ethical framework concerning human challenge studies.
32829985 2020. SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues.
32840856 2020. Coronavirus Human Infection Challenge Studies: Assessing Potential Benefits and Risks.
33046591 2020. Payment of COVID-19 challenge trials: underpayment is a bigger worry than overpayment.
32978304 2020. SARS-CoV-2 challenge studies: ethics and risk minimisation.
32978306 2020. Payment in challenge studies: ethics, attitudes and a new payment for risk model.
33082550 2020. Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials.
33087558 2020. Opinion: A risk-benefit framework for human research during the COVID-19 pandemic.
33087904 2020. Immunological considerations for SARS-CoV-2 human challenge studies.
33122444 2020. Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 vaccine development.
33137284 2020. COVID-19 human challenge studies in the UK.
33154089 2020. Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?
33235368 2020. The COVID vaccine challenges that lie ahead.
33236048 2020. Challenge Trials: What Are the Ethical Problems?
33249450 2020. Assessment of risks associated with SARS-CoV-2 experimental human infection studies.